Bortin M M, Gale R P, Rimm A A
JAMA. 1981 Mar 20;245(11):1132-9.
Comprehensive data were reported to the International Bone Marrow Transplant Registry by 24 worldwide teams regarding 144 patients with severe aplastic anemia who were treated with HLA-identical, allogeneic bone marrow transplantation between 1975 and 1978. One hundred fourteen patients received one transplant and 30 received two. Sustained engraftment of donor marrow occurred on the first transplant attempt in 76% of the patients whose engraftment status could be evaluated. Moderate, severe, or lethal graft-vs-host disease (GVHD) occurred in 52% of the engrafted patients. The one-year survival rate for all patients was 44% (64/144). Among the one-year survivors, the primary disease was apparently cured in 90% and improved in 10%. Thus far, four patients died one to five years after transplant. Of the 60 patients currently alive, ten have chronic GVHD and the remainder are in good health. Multivariate analyses of the data disclosed a number of pretransplant factors associated with engraftment, GVHD, and one-year survival. The most important finding was that the use of male donors was preferable to female donors because of a higher rate of engraftment, less severe GVHD, and a higher one-year survival rate.
24个全球团队向国际骨髓移植登记处报告了综合数据,这些数据涉及1975年至1978年间接受HLA匹配的异基因骨髓移植治疗的144例严重再生障碍性贫血患者。114例患者接受了一次移植,30例接受了两次移植。在可评估植入状态的患者中,76%在首次移植尝试时实现了供体骨髓的持续植入。52%的植入患者发生了中度、重度或致死性移植物抗宿主病(GVHD)。所有患者的一年生存率为44%(64/144)。在一年幸存者中,90%的患者原发性疾病明显治愈,10%有所改善。到目前为止,有4例患者在移植后1至5年死亡。在目前存活的60例患者中,10例患有慢性GVHD,其余患者健康状况良好。对数据的多变量分析揭示了一些与植入、GVHD和一年生存率相关的移植前因素。最重要的发现是,使用男性供体优于女性供体,因为植入率更高、GVHD较轻且一年生存率更高。